Cwm LLC Buys 384 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Cwm LLC grew its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 18.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,435 shares of the company’s stock after buying an additional 384 shares during the period. Cwm LLC’s holdings in Ionis Pharmaceuticals were worth $73,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Ionis Pharmaceuticals by 3,786.5% in the 1st quarter. GAMMA Investing LLC now owns 28,993 shares of the company’s stock worth $961,000 after purchasing an additional 28,247 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Ionis Pharmaceuticals by 4.8% in the first quarter. Fifth Third Bancorp now owns 9,989 shares of the company’s stock valued at $301,000 after purchasing an additional 458 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the fourth quarter worth $3,692,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Ionis Pharmaceuticals by 20.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,450 shares of the company’s stock worth $330,000 after buying an additional 1,625 shares during the period. Finally, Orbimed Advisors LLC boosted its holdings in shares of Ionis Pharmaceuticals by 21.2% during the 4th quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company’s stock worth $98,494,000 after buying an additional 492,900 shares during the period. Institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on IONS shares. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price (up previously from $50.00) on shares of Ionis Pharmaceuticals in a report on Thursday. Guggenheim dropped their price objective on Ionis Pharmaceuticals from $65.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Raymond James Financial boosted their price objective on Ionis Pharmaceuticals from $60.00 to $64.00 and gave the stock a “strong-buy” rating in a research report on Thursday. JPMorgan Chase & Co. raised their target price on Ionis Pharmaceuticals from $45.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, June 12th. Finally, Needham & Company LLC dropped their price target on Ionis Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.79.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $43.03 on Friday. The firm has a market capitalization of $6.86 billion, a PE ratio of -23.39 and a beta of 0.25. The company has a current ratio of 2.87, a quick ratio of 9.62 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $50.43. The business’s 50 day moving average is $39.07 and its 200-day moving average is $34.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.19 by $0.51. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%. The firm had revenue of $452.00 million during the quarter, compared to analysts’ expectations of $270.90 million. During the same period last year, the business earned ($0.45) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 100.9% compared to the same quarter last year. Sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Insider Activity at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 2,432 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $45.00, for a total transaction of $109,440.00. Following the sale, the chief executive officer directly owned 179,820 shares in the company, valued at approximately $8,091,900. The trade was a 1.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.